Outcomes for endoscopic submucosal dissection of pathologically staged T1b esophageal cancer: a multicenter study

Published:February 22, 2022DOI:https://doi.org/10.1016/j.gie.2022.02.018

      Background and Aims

      The outcomes of endoscopic submucosal dissection (ESD) for T1b esophageal cancer (EC) and its recurrence rates remain unclear in the West. Using a multicenter cohort, we evaluated technical outcomes and recurrence rates of ESD in the treatment of pathologically staged T1b EC.


      We included patients who underwent ESD of T1b EC at 7 academic tertiary referral centers in the United States (n = 6) and Brazil (n = 1). We analyzed demographic, procedural, and histopathologic characteristics and follow-up data. Time-to-event analysis was performed to evaluate recurrence rates.


      Sixty-six patients with pathologically staged T1b EC after ESD were included in the study. A preprocedure staging EUS was available in 54 patients and was Tis/T1a in 27 patients (50%) and T1b in 27 patients (50%). En-bloc resection rate was 92.4% (61/66) and R0 resection rate was 54.5% (36/66). Forty-nine of 66 patients (74.2%) did not undergo surgery immediately after resection and went on to surveillance. Ten patients had ESD resection within the curative criteria, and no recurrences were seen in a 13-month (range, 3-18.5) follow-up period in these patients. Ten of 39 patients (25.6%) with noncurative resections had residual/recurrent disease. Of the 10 patients with noncurative resection, local recurrence alone was seen in 5 patients (12.8%) and metastatic recurrence in 5 patients (12.8%). On univariate analysis, R1 resection had a higher risk of recurrent disease (hazard ratio, 6.25; 95% confidence interval, 1.29-30.36; P = .023).


      EUS staging of T1b EC has poor accuracy, and a staging ESD should be considered in these patients. ESD R0 resection rates were low in T1b EC, and R1 resection was associated with recurrent disease. Patients with noncurative ESD resection of T1b EC who cannot undergo surgery should be surveyed closely, because recurrent disease was seen in 25% of these patients.


      CRT (chemoradiation therapy), EAC (esophageal adenocarcinoma), EC (esophageal cancer), ESCC (esophageal squamous cell carcinoma), ESD (endoscopic submucosal dissection), LVI (lymphovascular invasion)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • et al.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • et al.
        Cancer statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
        • The Society of Thoracic Surgeons General Thoracic Surgery Database Task Force
        The Society of Thoracic Surgeons Composite Score for Evaluating Esophagectomy for Esophageal Cancer.
        Ann Thorac Surg. 2017; 103: 1661-1667
        • He H.
        • Chen N.
        • Hou Y.
        • et al.
        Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis.
        Thorac Cancer. 2020; 11: 1121-1128
        • Pech O.
        • May A.
        • Manner H.
        • et al.
        Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus.
        Gastroenterology. 2014; 146: 652-660
        • Ell C.
        • May A.
        • Gossner L.
        • et al.
        Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus.
        Gastroenterology. 2000; 118: 670-677
        • Leers J.M.
        • DeMeester S.R.
        • Oezcelik A.
        • et al.
        The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens.
        Ann Surg. 2011; 253: 271-278
        • Weusten B.
        • Bisschops R.
        • Coron E.
        • et al.
        Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement.
        Endoscopy. 2017; 49: 191-198
        • Sharma P.
        • Shaheen N.J.
        • Katzka D.
        • et al.
        AGA clinical practice update on endoscopic treatment of barrett's esophagus with dysplasia and/or early cancer: expert review.
        Gastroenterology. 2020; 158: 760-769
        • Mejia Perez L.K.
        • Yang D.
        • Draganov P.V.
        • et al.
        Endoscopic submucosal dissection vs. endoscopic mucosal resection for early Barrett's neoplasia in the West: a retrospective study.
        Endoscopy. 2022; 54: 439-446
        • Codipilly D.C.
        • Dhaliwal L.
        • Oberoi M.
        • et al.
        Comparative outcomes of cap assisted endoscopic resection and endoscopic submucosal dissection in dysplastic Barrett's esophagus.
        Clin Gastroenterol Hepatol. 2020; 20: 65-73.e1
        • Othman M.O.
        • Bahdi F.
        • Ahmed Y.
        • et al.
        Short-term clinical outcomes of non-curative endoscopic submucosal dissection for early esophageal adenocarcinoma.
        Eur J Gastroenterol Hepatol. 2021; 33: e700-e708
        • Harris P.A.
        • Taylor R.
        • Thielke R.
        • et al.
        Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support.
        J Biomed Inform. 2009; 42: 377-381
        • Harris P.A.
        • Taylor R.
        • Minor B.L.
        • et al.
        The REDCap consortium: building an international community of software platform partners.
        J Biomed Inform. 2019; 95: 103208
        • Bhatt A.
        • Abe S.
        • Kumaravel A.
        • et al.
        Indications and techniques for endoscopic submucosal dissection.
        Am J Gastroenterol. 2015; 110: 784-791
        • Bhatt A.
        • Mehta N.A.
        • Abe S.
        • et al.
        A novel curved wire retraction device for endoscopic submucosal dissection.
        VideoGIE. 2021; 6: 342-343
        • Yoshida M.
        • Takizawa K.
        • Nonaka S.
        • et al.
        Conventional versus traction-assisted endoscopic submucosal dissection for large esophageal cancers: a multicenter, randomized controlled trial (with video).
        Gastrointest Endosc. 2020; 91: 55-65
        • Abe S.
        • Iyer P.G.
        • Oda I.
        • et al.
        Approaches for stricture prevention after esophageal endoscopic resection.
        Gastrointest Endosc. 2017; 86: 779-791
        • Bhatt A.
        • Mehta N.A.
        Stricture prevention after esophageal endoscopic submucosal dissection.
        Gastrointest Endosc. 2020; 92: 1187-1189
        • Pimentel-Nunes P.
        • Dinis-Ribeiro M.
        • Ponchon T.
        • et al.
        Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) guideline.
        Endoscopy. 2015; 47: 829-854
        • Draganov P.V.
        • Wang A.Y.
        • Othman M.O.
        • et al.
        AGA Institute clinical practice update: endoscopic submucosal dissection in the United States.
        Clin Gastroenterol Hepatol. 2019; 17: 16-25
        • Abe S.
        • Ishihara R.
        • Takahashi H.
        • et al.
        Long-term outcomes of endoscopic resection and metachronous cancer after endoscopic resection for adenocarcinoma of the esophagogastric junction in Japan.
        Gastrointest Endosc. 2019; 89: 1120-1128
        • Yang D.
        • Coman R.M.
        • Kahaleh M.
        • et al.
        Endoscopic submucosal dissection for Barrett's early neoplasia: a multicenter study in the United States.
        Gastrointest Endosc. 2017; 86: 600-607
        • Podboy A.
        • Kolahi K.S.
        • Friedland S.
        • et al.
        Endoscopic submucosal dissection is associated with less pathologic uncertainty than endoscopic mucosal resection in diagnosing and staging Barrett's-related neoplasia.
        Dig Endosc. 2020; 32: 346-354
        • van Munster S.
        • Verheij E.
        • Nieuwenhuis E.
        • et al.
        Extending treatment criteria for Barrett's neoplasia: results of a nationwide cohort of 138 ESDs.
        Endoscopy. 2021; (Epub 2021 Sep 30)
        • Otaki F.
        • Ma G.K.
        • Krigel A.
        • et al.
        Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study.
        Gastrointest Endosc. 2020; 92: 31-39
        • Zhuang X.
        • Xu M.
        • Chen Z.
        • et al.
        Predictors for submucosal fibrosis in patients with superficial squamous esophageal neoplasia undergoing endoscopic submucosal dissection.
        Clin Transl Gastroenterol. 2020; 11: e00188
        • Chang T.T.
        • Thakar D.
        • Weaver V.M.
        Force-dependent breaching of the basement membrane.
        Matrix Biol. 2017; 57-58: 178-189
        • Cao Y.
        • Liao C.
        • Tan A.
        • et al.
        Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract.
        Endoscopy. 2009; 41: 751-757
        • Wang A.Y.
        • Hwang J.H.
        • Bhatt A.
        • et al.
        AGA clinical practice update on surveillance after pathologically curative endoscopic submucosal dissection of early gastrointestinal neoplasia in the United States: commentary.
        Gastroenterology. 2021; 161: 2030-2040
        • Dhupar R.
        • Rice R.D.
        • Correa A.M.
        • et al.
        Endoscopic ultrasound estimates for tumor depth at the gastroesophageal junction are inaccurate: implications for the liberal use of endoscopic resection.
        Ann Thorac Surg. 2015; 100: 1812-1816
        • Minashi K.
        • Nihei K.
        • Mizusawa J.
        • et al.
        Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma.
        Gastroenterology. 2019; 157: 382-390
        • Namikawa K.
        • Yoshio T.
        • Yoshimizu S.
        • et al.
        Clinical outcomes of endoscopic resection of preoperatively diagnosed non-circumferential T1a-muscularis mucosae or T1b-submucosa 1 esophageal squamous cell carcinoma.
        Sci Rep. 2021; 11: 6554
        • Hsu M.-H.
        • Wang W.-L.
        • Chen T.-H.
        • et al.
        Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma in Taiwan.
        BMC Gastroenterol. 2021; 21: 308
        • Al-Kaabi A.
        • Schoon E.J.
        • Deprez P.H.
        • et al.
        Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience.
        Gastrointest Endosc. 2021; 93: 888-898
        • Zhang Y.
        • Ding H.
        • Chen T.
        • et al.
        Outcomes of endoscopic submucosal dissection vs esophagectomy for T1 esophageal squamous cell carcinoma in a real-world cohort.
        Clin Gastroenterol Hepatol. 2019; 17: 73-81

      Linked Article

      • T1b esophageal cancer: Is it time for endoscopic submucosal dissection to enter the stage?
        Gastrointestinal EndoscopyVol. 96Issue 3
        • Preview
          Esophageal endoscopic submucosal dissection (ESD) was initially pioneered and developed in Japan predominantly for the treatment of superficial esophageal squamous cell cancer (ESCC). In the past decade, there has been growing interest in esophageal ESD in the West, where esophageal adenocarcinoma (EAC) remains dominant over ESCC, which has seen an overall decline in the past few decades. Endoscopic resection in Barrett’s esophagus (BE) has been well validated as an important tool that can provide staging, prognosis, and eradication of BE-associated neoplasia and is uniformly recommended across societal guidelines for the management of high-grade dysplasia (HGD) and tumors confined to the muscularis mucosa (T1a).
        • Full-Text
        • PDF